10-Q: Cancer Capital Corp. Reports Third Quarter 2024 Results, Continues Search for Merger Opportunity

Cancer Capital Corp. reports a net loss of $8,436 for the third quarter of 2024 and continues to seek a merger or acquisition target.

Summary

• Cancer Capital Corp. has released its financial results for the third quarter of 2024, showing no revenue and a net loss of $8,436.
• The company's total liabilities increased to $487,713 as of September 30, 2024, compared to $465,549 at the end of 2023.
• The company's cash balance decreased to $4,109 from $16,157 at the end of the previous year.
• Cancer Capital Corp. is actively seeking a merger or acquisition with an operating company to generate revenue.
• The company's management acknowledges substantial doubt about its ability to continue as a going concern without securing additional financing or a merger.
• The company has relied on related parties and third parties for funding and has not established a consistent revenue stream.
• The company's general and administrative expenses for the nine months ended September 30, 2024, were $16,546, compared to $11,499 for the same period in 2023.
• Total other expenses, primarily interest on notes payable, were $17,665 for the nine months ended September 30, 2024, compared to $17,125 for the same period in 2023.
• The company's accumulated deficit increased to $536,804 as of September 30, 2024.

Sentiment

Score: 2

Explanation: The document paints a bleak picture of the company's financial health, with no revenue, increasing losses, and a significant going concern risk. The reliance on related party loans and the lack of effective internal controls further contribute to a negative sentiment.

Positives

• The company is actively seeking a merger or acquisition, which could provide a path to revenue generation and improved financial stability.

Negatives

• The company has not generated any revenue since its inception.
• The company has incurred significant losses and has negative cash flows from operations.
• The company's cash balance has decreased significantly.
• The company's liabilities have increased.
• The company is dependent on related parties and third parties for funding.
• The company's management has expressed substantial doubt about its ability to continue as a going concern.
• The company has a significant accumulated deficit.

Risks

• The company's ability to continue as a going concern is highly uncertain.
• The company is dependent on securing additional financing or a merger to continue operations.
• The company's lack of revenue generation poses a significant risk.
• The company's reliance on related party loans and services creates potential conflicts of interest.
• The company's internal controls are not effective due to a lack of personnel to ensure segregation of duties.
• The company may face challenges in finding a suitable merger or acquisition target.
• Any merger or acquisition could result in significant dilution for existing shareholders.

Future Outlook

The company anticipates continuing net losses until it acquires or merges with a business opportunity. Management intends to rely on advances or loans from management, significant stockholders, or third parties to meet cash requirements, but there are no written agreements guaranteeing future funds.

Management Comments

• Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements.
• Our plan is to combine with an operating company to generate revenue.
• Management expects net losses to continue until we acquire or merge with a business opportunity.

Industry Context

The company's situation is not uncommon for early-stage companies seeking a reverse merger or acquisition to gain public market access. The lack of revenue and reliance on external funding are typical challenges for such entities.

Comparison to Industry Standards

• It is difficult to compare Cancer Capital Corp. to industry standards due to its lack of revenue and ongoing search for a merger target.
• Many early-stage companies in similar situations often have limited operating history and rely heavily on external funding.
• The company's financial metrics are not comparable to established companies with revenue-generating operations.
• The company's reliance on related party loans is not uncommon for early-stage companies but can raise concerns about potential conflicts of interest.

Related Party Transactions

• A shareholder invoiced the Company for consulting, administrative and professional services and out-of-pocket costs.
• A shareholder loaned the Company funds in prior years, with notes bearing 8% interest and due on demand.
• Accrued interest on related party notes payable was $100,000 as of September 30, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future stock issuances.
• Employees are impacted by the uncertainty surrounding the company's future.
• Creditors face risk due to the company's limited cash and increasing liabilities.

Next Steps

• The company will continue to seek a merger or acquisition opportunity.
• The company will need to secure additional funding to continue operations.
• The company will continue to file Exchange Act reports.

Key Dates

Keywords

merger, acquisition, going concern, financial statements, net loss, liabilities, cash flow, related party transactions, operating expenses, capital resources